Klotho Therapeutics, a virtual biotech developing a kidney disease treatment based on its proprietar...Read More
Klotho Therapeutics, Inc., (KTI) is a privately held biotechnology company developing modified recombinant versions of the human protein Klotho that has shown great potential to delay diseases of aging and improve longevity. The company builds upon the $100+ million invested in Klotho related academic research that demonstrates how Klotho, a naturally occurring protein in humans and animals, can positively impact aging, cognition, kidney function, fibrosis, and cancer. KTI has worldwide patents pending on modified, recombinant Klotho proteins that can be readily manufactured using standard cell culture technology.
Powered by Froala Editor